罗科福鲁埃科尔-A:一种天然化合物,有可能减轻空气中细尘引起的炎症性疾病
Eun-Gyeong Lee1, Sung-Kun Yim2, Sang-Min Kang1
1Laboratory for Infection Disease Prevention, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Republic of Korea.
Medicina (Kaunas, Lithuania)
|January 25, 2025
概括
海藻化合物,特别是基基醇-A (PFF-A),有效地减少了细尘引起的细胞炎症. PFF-A作为一种自然疗法,有望用于控制与污染相关的炎症反应.
科学领域:
- 海洋天然产品 海洋天然产品
- 免疫学 免疫学 免疫学
- 环境健康 环境健康
背景情况:
- 由细尘 (FD) 颗粒引起的空气污染会导致炎症,过敏和皮肤问题.
- 海藻化合物正在探索潜在的抗炎性质.
- 研究海藻在缓解FD诱导的全身炎症中的作用.
研究的目的:
- 确定海藻衍生的抗炎化合物.
- 评估它们对FD诱导的炎症的疗效.
- 阐明作用的分子机制.
主要方法:
- 来自Ecklonia cava,Ecklonia stolonifera和Codium fragile的化合物的净化. 这种化合物可以从中提取.
- 使用NMR和LC-MS/MS进行结构分析.
- 在FD暴露的RAW 264.7细胞中评估抗炎作用.
主要成果:
- 烯可二醇-A (PFF-A) 证明对FD诱导的炎症具有显著的保护作用,没有细胞毒性.
- 通过NF-κB/MAPK路径调节,PFF-A抑制了IL-1β的表达.
- PFF-A降低了促炎和亡相关的基因表达,同时提高了BMP基因的调节.
结论:
- 化 (Phlorofucofucofuroeckol-A,简称PFF-A) 是一种强大的抗炎剂.
- PFF-A有效地对抗FD诱导的细胞炎症.
- PFF-A代表了与FD相关的炎症状况的有希望的自然治疗候选者.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
239
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
216
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
216
Drugs Used in Lower Respiratory Disorders: Overview
347
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
347
Antiasthma Drugs: Methylxanthines
190
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
190
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
174
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
174


